Cargando…

Molecular characterization of myotonic dystrophy fibroblast cell lines for use in small molecule screening

Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are common forms of adult onset muscular dystrophy. Pathogenesis in both diseases is largely driven by production of toxic-expanded repeat RNAs that sequester MBNL RNA-binding proteins, causing mis-splicing. Given this shared pathogenesis, we hypothes...

Descripción completa

Detalles Bibliográficos
Autores principales: Jenquin, Jana R., O’Brien, Alana P., Poukalov, Kiril, Lu, Yidan, Frias, Jesus A., Shorrock, Hannah K., Richardson, Jared I., Mazdiyasni, Hormoz, Yang, Hongfen, Huigens, Robert W., Boykin, David, Ranum, Laura P.W., Cleary, John Douglas, Wang, Eric T., Berglund, J. Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035709/
https://www.ncbi.nlm.nih.gov/pubmed/35479399
http://dx.doi.org/10.1016/j.isci.2022.104198
_version_ 1784693356456050688
author Jenquin, Jana R.
O’Brien, Alana P.
Poukalov, Kiril
Lu, Yidan
Frias, Jesus A.
Shorrock, Hannah K.
Richardson, Jared I.
Mazdiyasni, Hormoz
Yang, Hongfen
Huigens, Robert W.
Boykin, David
Ranum, Laura P.W.
Cleary, John Douglas
Wang, Eric T.
Berglund, J. Andrew
author_facet Jenquin, Jana R.
O’Brien, Alana P.
Poukalov, Kiril
Lu, Yidan
Frias, Jesus A.
Shorrock, Hannah K.
Richardson, Jared I.
Mazdiyasni, Hormoz
Yang, Hongfen
Huigens, Robert W.
Boykin, David
Ranum, Laura P.W.
Cleary, John Douglas
Wang, Eric T.
Berglund, J. Andrew
author_sort Jenquin, Jana R.
collection PubMed
description Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are common forms of adult onset muscular dystrophy. Pathogenesis in both diseases is largely driven by production of toxic-expanded repeat RNAs that sequester MBNL RNA-binding proteins, causing mis-splicing. Given this shared pathogenesis, we hypothesized that diamidines, small molecules that rescue mis-splicing in DM1 models, could also rescue mis-splicing in DM2 models. While several DM1 cell models exist, few are available for DM2 limiting research and therapeutic development. Here, we characterize DM1 and DM2 patient-derived fibroblasts for use in small molecule screens and therapeutic studies. We identify mis-splicing events unique to DM2 fibroblasts and common events shared with DM1 fibroblasts. We show that diamidines can partially rescue molecular phenotypes in both DM1 and DM2 fibroblasts. This study demonstrates the potential of fibroblasts as models for DM1 and DM2, which will help meet an important need for well-characterized DM2 cell models.
format Online
Article
Text
id pubmed-9035709
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-90357092022-04-26 Molecular characterization of myotonic dystrophy fibroblast cell lines for use in small molecule screening Jenquin, Jana R. O’Brien, Alana P. Poukalov, Kiril Lu, Yidan Frias, Jesus A. Shorrock, Hannah K. Richardson, Jared I. Mazdiyasni, Hormoz Yang, Hongfen Huigens, Robert W. Boykin, David Ranum, Laura P.W. Cleary, John Douglas Wang, Eric T. Berglund, J. Andrew iScience Article Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are common forms of adult onset muscular dystrophy. Pathogenesis in both diseases is largely driven by production of toxic-expanded repeat RNAs that sequester MBNL RNA-binding proteins, causing mis-splicing. Given this shared pathogenesis, we hypothesized that diamidines, small molecules that rescue mis-splicing in DM1 models, could also rescue mis-splicing in DM2 models. While several DM1 cell models exist, few are available for DM2 limiting research and therapeutic development. Here, we characterize DM1 and DM2 patient-derived fibroblasts for use in small molecule screens and therapeutic studies. We identify mis-splicing events unique to DM2 fibroblasts and common events shared with DM1 fibroblasts. We show that diamidines can partially rescue molecular phenotypes in both DM1 and DM2 fibroblasts. This study demonstrates the potential of fibroblasts as models for DM1 and DM2, which will help meet an important need for well-characterized DM2 cell models. Elsevier 2022-04-04 /pmc/articles/PMC9035709/ /pubmed/35479399 http://dx.doi.org/10.1016/j.isci.2022.104198 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Jenquin, Jana R.
O’Brien, Alana P.
Poukalov, Kiril
Lu, Yidan
Frias, Jesus A.
Shorrock, Hannah K.
Richardson, Jared I.
Mazdiyasni, Hormoz
Yang, Hongfen
Huigens, Robert W.
Boykin, David
Ranum, Laura P.W.
Cleary, John Douglas
Wang, Eric T.
Berglund, J. Andrew
Molecular characterization of myotonic dystrophy fibroblast cell lines for use in small molecule screening
title Molecular characterization of myotonic dystrophy fibroblast cell lines for use in small molecule screening
title_full Molecular characterization of myotonic dystrophy fibroblast cell lines for use in small molecule screening
title_fullStr Molecular characterization of myotonic dystrophy fibroblast cell lines for use in small molecule screening
title_full_unstemmed Molecular characterization of myotonic dystrophy fibroblast cell lines for use in small molecule screening
title_short Molecular characterization of myotonic dystrophy fibroblast cell lines for use in small molecule screening
title_sort molecular characterization of myotonic dystrophy fibroblast cell lines for use in small molecule screening
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035709/
https://www.ncbi.nlm.nih.gov/pubmed/35479399
http://dx.doi.org/10.1016/j.isci.2022.104198
work_keys_str_mv AT jenquinjanar molecularcharacterizationofmyotonicdystrophyfibroblastcelllinesforuseinsmallmoleculescreening
AT obrienalanap molecularcharacterizationofmyotonicdystrophyfibroblastcelllinesforuseinsmallmoleculescreening
AT poukalovkiril molecularcharacterizationofmyotonicdystrophyfibroblastcelllinesforuseinsmallmoleculescreening
AT luyidan molecularcharacterizationofmyotonicdystrophyfibroblastcelllinesforuseinsmallmoleculescreening
AT friasjesusa molecularcharacterizationofmyotonicdystrophyfibroblastcelllinesforuseinsmallmoleculescreening
AT shorrockhannahk molecularcharacterizationofmyotonicdystrophyfibroblastcelllinesforuseinsmallmoleculescreening
AT richardsonjaredi molecularcharacterizationofmyotonicdystrophyfibroblastcelllinesforuseinsmallmoleculescreening
AT mazdiyasnihormoz molecularcharacterizationofmyotonicdystrophyfibroblastcelllinesforuseinsmallmoleculescreening
AT yanghongfen molecularcharacterizationofmyotonicdystrophyfibroblastcelllinesforuseinsmallmoleculescreening
AT huigensrobertw molecularcharacterizationofmyotonicdystrophyfibroblastcelllinesforuseinsmallmoleculescreening
AT boykindavid molecularcharacterizationofmyotonicdystrophyfibroblastcelllinesforuseinsmallmoleculescreening
AT ranumlaurapw molecularcharacterizationofmyotonicdystrophyfibroblastcelllinesforuseinsmallmoleculescreening
AT clearyjohndouglas molecularcharacterizationofmyotonicdystrophyfibroblastcelllinesforuseinsmallmoleculescreening
AT wangerict molecularcharacterizationofmyotonicdystrophyfibroblastcelllinesforuseinsmallmoleculescreening
AT berglundjandrew molecularcharacterizationofmyotonicdystrophyfibroblastcelllinesforuseinsmallmoleculescreening